Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2835700 | 0.87 | SSTR4 (0.32) | — | |
| SCHEMBL925103 | 0.84 | HIF1A (0.32) | — | |
| SCHEMBL925391 | 0.75 | MEN1 (0.32) | GPR119 | |
| SCHEMBL925598 | 0.73 | HIF1A (0.33) | — | |
| SCHEMBL15579052 | 0.72 | MAPT (0.33) | — | |
| SCHEMBL3024798 | 0.72 | ADRB2 (0.34) | — | |
| SCHEMBL3160941 | 0.72 | MT-CO2 (0.38) | MT-CO2 | |
| SCHEMBL1242387 | 0.70 | NPC1 (0.40) | MT-CO2 | |
| SCHEMBL14830378 | 0.70 | MT-CO2 (0.51) | MT-CO2 | |
| SCHEMBL1974012 | 0.70 | MEN1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150239862-A1 | PROCESS FOR THE PREPARATION OF VILANTEROL AND INTERMEDIATES THEREOF | PERRIGO API LTD. (IL) | 2015-08-27 | — | — | US | claimed |
| WO-2014041565-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF VILANTEROL AND INTERMEDIATES THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2014-03-20 | — | — | WO | claimed |
| CN-116024187-B | Enzymatic preparation method of vilantrum Luo Zhongjian | 合肥大学 | 2024-04-26 | — | — | CN | disclosed |
| CN-116024187-B | Enzymatic preparation method of vilantrum Luo Zhongjian | 合肥大学 | 2024-04-26 | — | — | CN | disclosed |
| CN-114736186-B | Method for synthesizing Violet Luo Zhongjian body from tert-butyl carbamate | 安徽德信佳生物医药有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20150239862-A1 | PROCESS FOR THE PREPARATION OF VILANTEROL AND INTERMEDIATES THEREOF | PERRIGO API LTD. (IL) | 2015-08-27 | — | — | US | disclosed |
| US-RE44874-E1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2014-04-29 | — | — | US | disclosed |
| WO-2014041565-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF VILANTEROL AND INTERMEDIATES THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2014-03-20 | — | — | WO | disclosed |
| EP-2042168-B1 | Inhalation formulation comprising phenethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LTD (GB) | 2013-10-23 | — | — | EP | disclosed |
| US-8198483-B2 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2012-06-12 | — | — | US | disclosed |
| US-20110269970-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| EP-1360174-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-11-12 | — | — | EP | disclosed |
| WO-2003091204-A1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003072539-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003035668-A2 | NOVEL ANTI-INFLAMMATORY ANDROSTANE DERIVATIVES -17-CARBOXY-LACTONE SUBSTITUTED STEROIDS WITH AN ARYL-CARBOXYLIC ESTER IN POSITION 17.ALPHA | GLAXO GROUP LIMITED (GB) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003024439-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002100879-A1 | NOVEL ANTI-INFLAMMATORY 17.ALPHA.-HETEROCYCLIC-ESTERS OF 17.BETA.CARBOTHIOATE ANDROSTANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002088167-A1 | ANTI-INFLAMMATORY 17.BETA.-CARBOTHIOATE ESTER DERIVATIVES OF ANDROSTANE WITH A CYCLIC ESTER GROUP IN POSITION 17.ALPHA | GLAXO GROUP LIMITED (GB) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002070490-A1 | AGONISTS OF BETA-ADRENOCEPTORS | GLAXO GROUP LIMITED (GB) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002066422-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239862-A1 | PROCESS FOR THE PREPARATION OF VILANTEROL AND INTERMEDIATES THEREOF | VAT1, VKORC1L1, VKORC1 | MT-CO2 1665/4885GPR119 1626/4885 |
| US-20110269970-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | PNMT, HRH2, CHKB | MT-CO2 169/4885GPR119 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.